|
|
|
| CDMO Of The Year: Cell & Gene Therapy | The CDMO Leadership Awards are based on feedback from biopharma sponsor companies and independently analyzed by Tufts Center for the Study of Drug Development. MilliporeSigma is proud to announce their distinction as 2026’s Cell & Gene Therapy CDMO of the year, and best in class distinctions for: Biologics – Technology Use and Cell & Gene Therapy - Analytical Services, Overall Staff, Project Management, Cultural Fit, Technology Use. More. |
|
|
|
|
|
| Redefining CAR-T Speed And Strength: A Conversation | Q&A | Resilience | Discover how an autologous CAR-T platform is addressing challenges in cell therapy manufacturing. A three-day process shortens cycles, improves T-cell potency and durability, and reduces costs. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | “My business model when I took over in 2017 was to outsource everything.” That’s as clear as it gets from a biotech CEO. Amit Kumar cuts to the chase during our conversation centered on the newly announced relationship between his company, Anixa Biosciences, and Cytovance Biologics, a U.S.-based CDMO. | |
|
|
Streamlining Post-Approval Changes For Lean Teams | By Megha Sinha, Kamet Consulting Group | As the regulatory landscape continues to evolve, cell and gene therapy companies must plan post-approval change programs with regulatory monitoring built in from the start. |
|
|
Leveraging Legacy Chemical Infrastructure For Domestic Supply Security | By Louis Garguilo, chief editor, Outsourced Pharma | Well, that didn’t work out as planned, writes Chief Editor Louis Garguilo, referring to Kodak's plan in 2018 to revitalize the Eastman Business Park in Rochester, NY. The incoming chairman and now CEO, Jim Continenza, didn’t like that movie, and flipped the script. Instead, Kodak has, so to speak, returned to itself – back to a domestic specialty materials and chemicals supplier, intent on serving biopharma in that capacity. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
| Balancing Early-Stage Needs With Future Success | Article | By Omar Baez, Comprehensive Cell Solutions | Streamlining the tech transfer process is a key variable in shortening development timelines and controlling costs, maximizing a molecule's potential for late-stage success. |
|
|
| Pioneering Affordable CAR-T Cell Therapies In India | Article | By Dr. Phalguni Deswal, MBBS, MSc, ACMI, Vector BioMed | CAR-T cell therapy is poised to transform cancer care in India, with new initiatives aiming to make this breakthrough treatment both clinically feasible and financially accessible. |
|
|
| Maximize Output From Full-Time Employees | Case Study | Eurofins PSS Insourcing Solutions | Learn about project-based insourcing solutions designed to give clients laboratory services support with flexible timeframes, and eliminate worries about co-employment and other regulatory concerns. |
|
|
| How To Choose The Right CDMO | Article | By Amalia Soenens & Lindsey Wolf, Landmark Bio | Advanced therapy manufacturing requires deep biological expertise. Choosing a partner with translational experience and a robust CMC strategy is vital to navigating complex regulatory reviews. |
|
|
|
|
| Vendor To Visionary: Transforming AAV Manufacturing | Article | By Artur Padzik, 3PBIOVIAN | Early, collaborative CDMO partnerships optimize AAV development, enhancing manufacturability and reducing risks to shorten timelines more effectively than traditional transactional models. |
|
|
| Synthetic DNA As An Alternative For Scalable Viral Vector Production | White Paper | By Cindy Muralles, Kyle Sylakowski, Chad C. MacArthur, et al., Touchlight | Enzymatically synthesized DNA is assessed as a plasmid alternative, showing comparable viral vector yield, quality, and purification, while improving scalability and regulatory flexibility. |
|
|
| A Faster Path To Genomic Medicine Feasibility | White Paper | ElevateBio | Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress. |
|
|
|
|
| Outsourced Pharma Capabilities Update July 2026: Gene Therapy (July 28, 11am ET) | As gene therapy programs advance toward scalable, regulated manufacturing, early decisions carry greater risk and complexity. This session explores how leading CDMOs support end to end development, from process design to GMP production and commercialization. Experts will discuss strategies that reduce downstream risks, improve scalability, and streamline tech transfer, offering practical insight into how CDMO choices impact success across the product lifecycle. Learn more. |
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
